Navigation Links
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
Date:1/7/2008

SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033. The collaboration will focus on completing all necessary studies for submission of an investigational new drug application (IND), as well as clinical development and commercialization of TT-033.

"We are very pleased about forming a collaborative relationship with Pfizer, and are excited about being first in the industry to partner an expressed RNAi drug," said Sara M. Hall, Chief Executive Officer of Tacere. "We have made excellent progress in the research and preclinical development of TT-033, and are very happy to be joined by Pfizer at an important time in the program's development. Pfizer recognizes the potential of this first-in- class approach to provide a novel treatment option for HCV patients and we look forward to working with the team at Pfizer to advance TT-033."

Mike Catelani, Chairman, President and CFO of Tacere, stated, "We look forward to combining Pfizer's and Tacere's complementary capabilities to take TT-033 into the clinic. We are pleased that Pfizer has chosen to work with us in developing this potential single administration RNAi drug to aid in the fight against the global healthcare crisis of HCV."

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical research and development efforts for TT-033. Pfizer will fund all aspects of the collaboration, including the preclinical development work and will have exclusive worldwide rights, excluding all Asian countries, to commercialize products that result from the collaboration.

During the initial phase of the collaboration, Pfizer will provide Tacere with funding in order to complete the necessary IND-enabling studies
'/>"/>

SOURCE Tacere Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a leading ... showing its latest designs of wedding dresses and launching a ... CEO, all the fresh new products are designed for 2015, ... 80% off. All the clothes from LunaDress follow up with ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer and ... cast the,presentation by Harvey Kamil, President and Chief Financial ... in New York on Wednesday,September 17, 2008., The ... NBTY,s web site, (http://www.nbty.com ) on Wednesday, September 17, ...
... Calif., Sept. 11 Abaxis, Inc.,(Nasdaq: ABAX ), ... today that Clint Severson, CEO and,President, will present at ... 17, 2008 at 8:00 a.m. EDT, at the Omni ... Abaxis develops, manufactures and markets portable blood analysis,systems ...
... Kurian, MD, and her colleagues at the Stanford University ... identify women who might have dangerous genetic mutations that ... well for white women. But they seemed to be ... repeatedly surprised when Asian women who the models predicted ...
... Wolters Kluwer Health, a,division of Wolters Kluwer, ... for students, professionals, and institutions in medicine,nursing, ... announced,today the appointment of Scott Lubeck Vice ... Lubeck comes to Wolters Kluwer Health ...
... Sept. 11 Vasculitis,Foundation (VF), the leading organization ... all types of vasculitis, is taking,its advocacy and ... of its,first-ever webinar, Monday, September 22, 12:30 - ... easily accessible information about,vasculitis to the medical community ...
... newly-developed technology at the Delft University of Technology in the ... be a thing of the past. This is the message ... Institute Delft (RID) in an article in university journal ... hospitals are facing a shortage of radio isotopes which means ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 3Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease 2Health News:Delft University of Technology patent for manufacturing radio isotopes 2
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
The Finstrip 4 is an effective and reliable microplate washer offering high performance, simplicity and ease of use....
... Bio-Rad's Model 1575 immunowash ... control of needle position ... routines and maximize wash ... a large choice of ...
... a solid made, manual plate washer ... for dispense and aspirate function ensure ... with a stand and all necessary ... used, as well as any bottles ...
Medicine Products: